Gordon Cook

Active 1965–2025

155
Papers
18,915
Citations
81
h-index
149
i10-index

Citations

Citations per year for Gordon Cook1966: 3 citations1967: 5 citations1968: 2 citations1969: 5 citations1970: 4 citations1971: 9 citations1972: 9 citations1973: 5 citations1974: 4 citations1975: 4 citations1976: 9 citations1977: 2 citations1978: 3 citations1979: 1 citations1980: 5 citations1981: 4 citations1982: 2 citations1983: 3 citations1984: 3 citations1985: 3 citations1986: 2 citations1987: 4 citations1988: 5 citations1989: 2 citations1990: 2 citations1992: 4 citations1993: 5 citations1994: 7 citations1995: 7 citations1996: 6 citations1997: 2 citations1998: 10 citations1999: 14 citations2000: 10 citations2001: 13 citations2002: 11 citations2003: 14 citations2004: 8 citations2005: 25 citations2006: 27 citations2007: 36 citations2008: 43 citations2009: 46 citations2010: 54 citations2011: 74 citations2012: 93 citations2013: 111 citations2014: 95 citations2015: 107 citations2016: 84 citations2017: 111 citations2018: 131 citations2019: 459 citations2020: 599 citations2021: 772 citations2022: 612 citations2023: 427 citations2024: 753 citations2025: 328 citations2026: 7 citations1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,736 citing papers, 19.9% of this breakdownUnited Kingdom: 790 citing papers, 9% of this breakdownGermany: 601 citing papers, 6.9% of this breakdownItaly: 539 citing papers, 6.2% of this breakdownFrance: 481 citing papers, 5.5% of this breakdownSpain: 419 citing papers, 4.8% of this breakdownChina: 341 citing papers, 3.9% of this breakdownNetherlands: 283 citing papers, 3.2% of this breakdownCanada: 262 citing papers, 3% of this breakdownAustralia: 243 citing papers, 2.8% of this breakdownGreece: 210 citing papers, 2.4% of this breakdownSwitzerland: 204 citing papers, 2.3% of this breakdown
0%19.9%Other 30.1%

Fields

  • Medicine75.8%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology6.4%
  • Earth and Planetary Sciences0.8%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Social Sciences0.4%
  • Other2.3%

Topics

  • Multiple Myeloma Research and Treatments13.8%
  • Protein Degradation and Inhibitors6.3%
  • CAR-T cell therapy research3.4%
  • Hematopoietic Stem Cell Transplantation3.1%
  • Peptidase Inhibition and Analysis3.1%
  • Immune Cell Function and Interaction2.9%
  • Other67.4%

Coauthors

All papers

Open in search
  1. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 820

  2. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 cited by 407

  3. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 178

  4. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 564

  5. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

    Authors: , , , , , , , , , - British Journal of Haematology 2012 cited by 220

  6. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc S. Raab, Fritz Van Rhee, Saad Z. Usmani, Kenneth H. Shain, Niels Weinhold, Gareth J. Morgan, Ola Landgren - Journal of Clinical Oncology 2024 cited by 119

  7. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  8. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 141

  9. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , C.J. Duncan, Donal Skelly, Barbara Kronsteiner, Priyanka Abraham, Eloise Phillips, Katie Jeffery, Lance Turtle, Lisa Frending, Lizzie Stafford, Mohammad Ali, Patpong Rongkard, Rebecca Payne, Sandra Adele, Simon Travis, Siobhan Gardiner, Sue L. Dobson, Tom Malone, Sagida Bibi, Miles W. Carroll, Sian Faustini, Sarah Foulkes, John Frater, Victoria Hall, Susan Hopkins, Jasmin Islam, Teresa Lambe, Stephanie Longet, Shona C. Moore, Ashley Otter, Sarah Rowland‐Jones, James E. D. Thaventhir, Dan Wootton, Neil Basu, Ashley Gilmour, Sophie Irwin, Georgina Meacham, Thomas Marjot, Stavros Dimitriadis, Peter Kelleher, Maria Prendecki, Candice Clarke, Paige M Mortimer, Stacey McIntyre, Rachael Selby, Naomi Meardon, Dung Nguyen, Tom Tipton, Stephanie Longet, Stephen M. Laidlaw, Kim Orchard, Georgina Ireland, CONSENSUS, Kevin Brown, Gayatri Amirthalingam, David Thomas, Pamela Kearns, Amanda Kirkham, Iain B. McInnes, OCTAVE Collaborative Group, Richard Beesley, Vicky Churchill, Holly Loughton, Elspeth Insch, Eilean MacDonald, Gary Middleton, Lucinda Billingham, Faye Lowe, Sophia Magwaro, Saly Al‐Taei, Maxine Arnott and 59 more - Nature Medicine 2023 cited by 133

  10. The Beaker phenomenon and the genomic transformation of northwest Europe

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jorge Vega Miguel, Roberto Menduiña García, Azucena Avilés Fernández, Eszter Bánffy, Maria Bernabò-Brea, David Billoin, Clive Bonsall, Laura Bonsall, Tim Allen, Lindsey Büster, Sophie Carver, Laura Castells Navarro, Oliver E. Craig, Gordon Cook, Barry Cunliffe, Anthony Denaire, Kirsten Egging Dinwiddy, Natasha Dodwell, Michal Ernée, Chris Evans, Milan Kuchařík, Joan Francès i Farré, Chris Fowler, Michiel Gazenbeek, Rafael Garrido Peña, María Haber Uriarte, Elżbieta Haduch, Gill Hey, Nick Jowett, Timothy Knowles, Ken Massy, Saskia Pfrengle, Philippe Lefranc, Olivier Lemercier, Arnaud Lefèbvre, César Heras Martínez, Virginia Galera Olmo, Ana B. Bastida Ramírez, Joaquín Lomba Maurandi, Tona Majó, Jacqueline I. McKinley, Kathleen McSweeney, Balázs Gusztáv Mende, Alessandra Modi, Gabriella Kulcsár, Viktória Kiss, András Czene, R Patay, Anna Endrődi, Kitti Köhler, Tamás Hajdu, Tamás Szeniczey, János Dani, Zsolt Bernert, Maya Hoole, Olivia Cheronet, Denise Keating, Petr Velemínský, Miroslav Dobeš, Francesca Candilio, Fraser Brown, Raúl Flores Fernández, Ana Mercedes Herrero Corral, Sebastiano Tusa, Emiliano Carnieri, Luigi Lentini, Antonella Valenti, Alessandro Zanini, Clive Waddington, Germán Delibes and 44 more - Nature 2018 cited by 784

  11. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 110

  12. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2017 cited by 235

  13. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 340

  14. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 cited by 318

  15. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2022 cited by 123

  16. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 85

  17. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

    Authors: , , , , , , , , , , , , , , , , , - Haematologica 2021 cited by 85

  18. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 659

  19. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva - Leukemia 2020 cited by 119

  20. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

    Authors: , , , , , , , , , - Leukemia 2017 cited by 305

  21. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review

    Authors: , , , , , , , , , , , , , , , - Blood Cancer Journal 2023 cited by 68

  22. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Authors: , , , , , , , , , , , , , , , - Blood Cancer Journal 2021 cited by 114

  23. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2012 cited by 398

  24. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , - Leukemia 2020 cited by 238